Biopharma companies are sitting on roughly $1.2 trillion in firepower, according to a recent report by Ernst & Young. But firepower to spend on deals — which includes cash, existing debt, and market capitalization — won’t necessarily translate into multibillion-dollar transactions, at least in the short term.
Real-world data (RWD) and real-world evidence (RWE) can be relevant and essential to bringing innovation to patients and gaining regulatory approval. This article describes the sources of real-world data, how to use real-world data to enhance a development program, and how RWD and RWE advance regulatory decision-making.
Tufts CSDD is conducting an important new survey to assess how pharma and biotech companies are incorporating patient engagement into their drug development organizations and operations. Take the survey here.
Every initiative to improve healthcare requires high-quality data. Whether an organization is seeking improved outcomes, higher quality, or lower costs, learn why it should start with in-depth, reliable, and representative data.
Explore four key interconnected variables exerting pressure on therapeutics developers to improve their processes earlier in the product’s development.
Experts at Sartorius discuss the challenges complex molecules present to drug manufacturers today and the vital role suppliers play in fulfilling talent gaps for their customers.
Together, nuclear magnetic resonance (NMR) and MS analysis can definitively identify reference standards, active pharmaceutical ingredients (APIs), or final drug product composition.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
